Allogeneic bone marrow transplantation for lymphoma

Research output: Contribution to journalReview article

24 Scopus citations

Abstract

Registry data show that use of allogeneic transplantation for non-Hodgkin's lymphoma, and to a lesser extent, Hodgkin's disease is increasing. Although no prospective randomized trials have been performed, most comparisons show a significantly lower relapse rate when allogeneic transplant results are compared to results of autologous hematopoietic stem cell transplantation. The lower relapse rate following allogeneic transplantation, as well as several other lines of evidence, support the existence of a graft-versus-lymphoma effect. Nevertheless, in most comparisons, the lower relapse rate following allogeneic transplantation is offset by higher transplant-related mortality. These results make it difficult to find situations where definite overall survival advantages associated with the use of allogeneic transplantation can be demonstrated. The use of low-intensity non-myeloablative regimens for allogeneic transplantation is attracting attention. It is hoped that this approach may harness a graft-versus-lymphoma effect with less morbidity and mortality than conventional allogeneic transplantation, but more data are required to assess the value of this treatment. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalBlood Reviews
Volume14
Issue number1
DOIs
StatePublished - Mar 2000

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Allogeneic bone marrow transplantation for lymphoma'. Together they form a unique fingerprint.

  • Cite this